Is there any prognostic importance of pretreatment serum M30 and serum M65 levels on progression-free survival of patients with metastatic renal cell carcinoma treated with first-line sunitinib?

dc.contributor.author	Darendeliler, Emin
dc.contributor.author	Yildiz, Ibrahim
dc.contributor.author	Kilic, Leyla
dc.contributor.author	Basaran, Mert
dc.contributor.author	Keskin, Serkan
dc.contributor.author	Sen, Fatma
dc.contributor.author	Bavbek, Sevil E.
dc.date.accessioned	2021-03-04T18:23:20Z
dc.date.available	2021-03-04T18:23:20Z
dc.identifier.citation	Basaran M., Yildiz I., Sen F., Kilic L., Keskin S., Darendeliler E., Bavbek S. E. , "Is there any prognostic importance of pretreatment serum M30 and serum M65 levels on progression-free survival of patients with metastatic renal cell carcinoma treated with first-line sunitinib?", 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31
dc.identifier.other	vv_1032021
dc.identifier.other	av_8a6a4518-cd56-4b53-96c9-b7b5aa174bff
dc.identifier.uri	http://hdl.handle.net/20.500.12627/93824
dc.language.iso	eng
dc.subject	Sağlık Bilimleri
dc.subject	Dahili Tıp Bilimleri
dc.subject	İç Hastalıkları
dc.subject	Onkoloji
dc.subject	Klinik Tıp (MED)
dc.subject	Tıp
dc.subject	Klinik Tıp
dc.subject	ONKOLOJİ
dc.title	Is there any prognostic importance of pretreatment serum M30 and serum M65 levels on progression-free survival of patients with metastatic renal cell carcinoma treated with first-line sunitinib?
dc.type	Bildiri
dc.contributor.department	, ,
dc.identifier.volume	31
dc.contributor.firstauthorID	141478

Files in this item

Files	Size	Format	View
There are no files associated with this item.